Fidaxomicin as first line: What will it cost in the USA and Canada?

Devangi Patel1 PharmD, Julien Senecal1 BSc, Brad Spellberg MD2, Andrew M. Morris3 MD MSc, Lynora Saxinger4 MD, Brent W. Footer5 PharmD, Emily G. McDonald6,7 MD MSc, and Todd C. Lee6,7,8 MD MPH FIDSA

1. Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada
2. Los Angeles County+University of Southern California Medical Center, Los Angeles, USA
3. Division of Infectious Diseases, Department of Medicine, Sinai Health, University Health Network, and University of Toronto, Toronto, Canada
4. Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada
5. Providence Portland Medical Center, Portland, USA
6. Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montréal, Canada
7. Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montréal, Canada
8. Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, Canada

Corresponding author:

Todd C. Lee MD MPH
1001 Decarie Blvd E5-1820
Montreal, QC
H4A3S1
todd.lee@mcgill.ca

Word Counts:
Key Points: 100
Abstract: 350
Main text: 2090

References: 25
Figures: 3
Tables: 1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
**Key Points:**

**Question:** At what price point does new guideline recommendations for changing from vancomycin to fidaxomicin for first line *C. difficile* infection (CDI) therapy become cost saving?

**Findings:** For a 10-day course, we estimated that compared to vancomycin, treatment with fidaxomicin costs an additional $46,178USD to prevent one CDI recurrence and that treating one recurrence costs $14,506USD. The current cost of fidaxomicin is only partially offset through prevention of recurrences. Upfront therapy with fidaxomicin would be cost saving if the price were reduced below $1550USD per treatment.

**Meaning:** New guideline updates could add billions in additional drug costs for CDI treatment.
Abstract:

Importance:
Recent changes in the Infectious Diseases and Healthcare Epidemiology Societies of America (IDSA-SHEA) guidelines for managing *Clostridioides difficile* infections (CDI) have placed fidaxomicin as first-line treatment for CDI.

Objective:
To estimate the net cost of first line fidaxomicin as compared to vancomycin in the American and Canadian healthcare systems and to estimate the price points at which fidaxomicin would become cost saving.

Data sources:
We identified all randomized controlled trials comparing fidaxomicin with vancomycin through the 2021 IDSA-SHEA guideline update. Medication costs were obtained from wholesale prices (US) and the Quebec drug formulary (Canada). The average cost of a CDI recurrence was established through two systematic reviews using PubMed.

Study selection:
For fidaxomicin efficacy, we included double-blind and placebo-controlled trials. For the systematic review of recurrence costs, studies were included if they were primary research articles, had a cost-analysis of CDI, included cases of recurrent CDI, and were calculated with cost parameters from American or Canadian healthcare systems. Studies were excluded if the population was solely pediatric or hospitalized.

Data extraction and Synthesis:
For the efficacy meta-analysis, data was pooled using a random effects model. For the costs review, literature screening was performed by 2 independent reviewers. The mean cost across identified studies was adjusted to 2021 dollars.

Main Outcomes and Measures:
The primary outcome of the meta-analysis was CDI recurrence at day 40. The primary outcome of the systematic review was the average cost of a CDI recurrence in the American and Canadian healthcare systems. The objective was to estimate the net cost per recurrence prevented and the price point below which fidaxomicin would be cost saving.

Results:
At current drug pricing, the estimated additional cost of a 10-day course of fidaxomicin compared to vancomycin in order to prevent one recurrence was $46,178USD (95%CI $36,942-$69,267) and $13,760CAD (95%CI $11,008-$20,640), respectively. The estimated mean systemic cost of a CDI recurrence was $14,506USD and $8,588CAD, respectively. When priced below $1550USD and $800CAD, fidaxomicin was likely to become cost saving.

Conclusions and Relevance:
The increased drug expenditure on fidaxomicin will not be offset through recurrence prevention unless fidaxomicin price is re-negotiated.
Introduction:

*Clostridioides difficile* infection (CDI) is a major cause of healthcare-associated diarrhea in North America. It is estimated that in 2017 there were nearly 462,000 cases in the United States (US) and in 2012\(^1\) there were approximately 37,900 cases in Canada\(^2\). Of these, 15-20% are recurrences. The prevention of incident and recurrent episodes of CDI is therefore an important public health goal. Several pharmacologic and nonpharmacologic interventions have been investigated as initial treatment, and more specifically for the prevention of recurrence. For much of the twenty-first century, the recommended initial treatment of CDI has been oral metronidazole or vancomycin. In 2011, Fidaxomicin was first demonstrated to be non-inferior to oral vancomycin for clinical cure; this was shown in 2 of 3 double-blind, randomized, placebo-controlled trials\(^3,4\), with all 3 providing evidence of a reduced risk of recurrence at day 40\(^3-5\). However, recommendations for fidaxomicin as first line therapy have lagged in guidelines and formulary uptake has been slow, presumably due to fidaxomicin’s higher cost. Issues surrounding affordability were highlighted in the 2017 Infectious Diseases and Healthcare Epidemiology Societies of America (IDSA-SHEA) guidelines\(^6\) and in the 2018 Association of Medical Microbiology and Infectious Diseases of Canada (AMMI) guidelines\(^7\). More than a decade since the initial trial was published, the 2021 update to the IDSA-SHEA *C. difficile* guidelines has now gone on to recommend fidaxomicin as first line therapy for all patients\(^8\). At the current pricing, treating all American and Canadian patients with fidaxomicin would cost an estimated $2.79 billion US dollars (USD) and $60 million Canadian dollars (CAD) per year, respectively. Whether the prevention of recurrent CDI will offset the higher up-front cost of fidaxomicin is unknown. We sought to estimate 1) the net (added) cost of first line use of fidaxomicin required to prevent a recurrence as compared to oral vancomycin and compare this with 2) the cost of a CDI recurrence, in order to determine 3) the price point where a treatment course with fidaxomicin becomes cost saving.

Methods:

To estimate the comparative efficacy of fidaxomicin vs. vancomycin we conducted a meta-analysis of the three double blind, placebo-controlled, randomized controlled trials identified by IDSA-SHEA\(^8\) wherein fidaxomicin was compared head-to-head with vancomycin\(^3,5\). We excluded a fourth trial which was open label and compared a longer total duration of fidaxomicin (30-days vs. 10-days in all other included studies)\(^9\). We examined the primary outcome of CDI recurrence at day 40, which was the longest common duration studied and meta-analyzed the risk ratio with 95% confidence intervals using a random effects restricted maximum likelihood model in STATA v. 17 (StataCorp LP). Using the overall control event rate as the expected baseline rate of recurrence, we then estimated the absolute risk difference and 95% confidence intervals by multiplying the baseline rate by 1 minus the risk ratio (or corresponding upper/lower boundary of the confidence interval). We then estimated the number needed to treat (NNT) by dividing 100 by the estimated absolute risk difference with confidence intervals.
We obtained estimates of the American drug costs from the actual wholesale price accessed on June 25, 2021 (by BWF) and Canadian drug costs from the Quebec formulary\(^{10}\) (the province with the highest rate of CDI). A 10-day course of fidaxomicin was estimated at $5,111.64USD and $1,584 CAD, and that of vancomycin at $493.84USD (Syrup) and $208 CAD (capsules). Using the NNT we estimated the additional drug cost per recurrence prevented with 95% confidence intervals.

Next, we estimated the cost of a CDI recurrence in USD and CAD through a systematic review of the literature. We searched PubMed on August 14, 2021 with the search terms described in the Supplement. We included studies that were primary research articles, contained a cost-analysis of CDI, included cases of recurrent CDI, and were calculated with cost parameters based on the American or Canadian healthcare systems. Studies were excluded if the population studied was solely pediatric or hospitalized patients. References for all included studies were examined for additional applicable studies. Screening and data extraction was performed in duplicate (DP, JS and TCL) with disagreement resolved by consensus. All costs were converted to 2021 dollars using the Consumer Price Index Inflation Calculator\(^{11}\) (USD) and Bank of Canada Inflation Calculator\(^{12}\) (CAD) respectively. Across included studies, the average cost for 2021 was calculated and used for the analysis.

Finally, we calculated the probability of various effect sizes from the baseline recurrence rate and 95% confidence interval associated with the relative risk. We then identified how probable it was, at a specified price for fidaxomicin (rounded to nearest $25), that the total cost of treating all patients with fidaxomicin relative to vancomycin would be offset by the cost savings from preventing recurrences (probability of cost equivalence). We created scatter plots of the probability of cost equivalence as a function of fidaxomicin price. For visualization purposes, a line of best fit was generated with curvefit\(^{13}\) for STATA with a rational estimator and the current price of fidaxomicin was included for reference.

**Results:**

**Fidaxomicin effectiveness:**

The overall relative risk for recurrence with 10 days of fidaxomicin vs. 10 days of vancomycin was 0.58 (95% CI 0.46-0.74; Figure 1). This corresponds to an absolute risk reduction of 10.8% (95% CI 6.7% - 14%) or a NNT of 10 (95% CI 8-15). At the current American fidaxomicin and vancomycin prices, the estimated additional cost to prevent one recurrence was estimated as $46,178 USD (95%CI $36,942-$69,267). At the current fidaxomicin and vancomycin prices in Quebec, Canada, this was estimated at $13,760CAD (95%CI $11,008-$20,640).

**Cost of recurrence:**
The results of the systematic literature review for the cost of a CDI recurrence in the American and Canadian healthcare systems are presented in Table 1. Additional descriptions of each included study are in the Supplement. For the USA, the initial search for the cost of a CDI recurrence yielded 732 results. Of these results, 97 articles were selected for further review. Of the 97 articles, 13 were reviews or meta-analyses, 34 included only hospitalized patients, 39 did not calculate the cost of a recurrent CDI episode, 3 included only a pediatric population, and 1 was not actually based in the US. The 7 remaining articles were retained for the final analysis. One article was subsequently excluded because it calculated the 12-month all-cause medical costs (as opposed to the attributable cost) of patients with recurrent CDI episodes. Additionally, Luo et al. calculated the cost of recurrent CDI based on differing treatment strategies; the cost of the treatment with fidaxomicin was excluded from the overall average.

The search for the cost of a recurrence in Canada yielded 117 results, of which 18 articles were reviewed based on the title and abstract. Of these 18 studies, 14 studies were excluded: 5 studies did not include cases of recurrent CDI, 4 studies did not measure the cost of CDI, 4 studies were literature reviews, and 1 study measured the cost of readmission to hospital due to CDI without specifying if it was for first episode or recurrence. Four remaining studies included cases of recurrent or relapsed CDI and their cost. One study that included cases of recurrent CDI was subsequently excluded as it presented the cost in median ($1812CAD), not mean values. This left 3 studies that were included in the Canadian analysis for the cost of recurrence.

The estimated mean 2021 systemic costs for a recurrence of CDI in the American and Canadian healthcare systems respectively were $14,506USD and $8,588CAD.

Cost equivalence:

With respect to the USA, at the current price for 10 days of fidaxomicin and for 10 days of vancomycin syrup, there is a 0% chance that fidaxomicin will be cost equivalent by preventing the next CDI recurrence (Figure 2). At a price of approximately $2,050 [$1,550 more than the current cost of 10-day course of vancomycin] the probability of cost equivalence rises to 50% and at approximately $1,550 [$1,050 more than vancomycin] the probability rises to 95%. Below $1,550 fidaxomicin is likely to be cost saving.

For Canada, at the current 10-day price of $1,580 CAD for fidaxomicin and $208 CAD for vancomycin, there is less than a 0.1% chance that fidaxomicin will be cost equivalent by preventing the next CDI recurrence (Figure 3). Reducing fidaxomicin price to approximately $1,100 CAD [$900 more than the current cost of a 10-day course of vancomycin] the probability of cost equivalence rises to 50% and at approximately $800 CAD [$600 more than vancomycin] the probability rises to 95%. In Canada, at any price below $800 CAD, fidaxomicin is likely to be cost saving.
Discussion:

From our detailed review of the literature and associated calculations, we found that for both the US and Canada, the use of fidaxomicin as first-line treatment for CDI at the current pricing costs substantially more than costs saved through preventing the next recurrence. We identified price-points of approximately $1,550 USD and $800 CAD at or below which the use of fidaxomicin is very likely to be cost equivalent or cost saving. Despite double-blind randomized placebo-controlled trial evidence that 10 days of fidaxomicin is superior to 10 days of vancomycin for the prevention of first recurrence at day 40, this efficacy has not translated into a meaningful uptake of fidaxomicin which we hypothesize is due to the very high financial impact. In Canada, individual provinces have their own drug plans, and negotiation with the manufacturer to obtain a more cost-equivalent price point is possible, which could facilitate a financially viable practice change. In the US, such negotiations are not currently permitted by Medicare by law; however, negotiation of pricing could save the US billions per year for all drugs, including fidaxomicin\textsuperscript{24}. Individual insurance companies, particularly ones with large formulary budgets and therefore more negotiating power, might be able to effectuate this.

This analysis has several limitations. At the current price of fidaxomicin, any strategy that increases the efficacy of vancomycin, for example, the use of an up-front decreasing dose taper to prevent recurrence (study NCT04138706), would impact our results and would require recalculation. We have presented a best-case scenario for fidaxomicin by comparing it to a 10-day course of vancomycin. Furthermore, the efficacy of fidaxomicin to prevent recurrence out to day 56 (the IDSA-SHEA definition of recurrence), or day 90, was not studied in the randomized trials. Up to 31\% of recurrences may happen after day 42\textsuperscript{25} and there is no RCT data to support robust comparisons between strategies to prevent delayed recurrences. The use of fidaxomicin in multiple recurrences has not been studied by a randomized controlled trial, but it is possible that preventing the next recurrence will prevent multiple recurrences. Finally, reducing the cost of vancomycin through the compounding of generic IV vancomycin into liquid form or more aggressive vancomycin syrup or capsule pricing would make the break-even price of fidaxomicin substantially higher.

A strength of our study is our novel approach of using a meta-analytic assessment of the effect size for fidaxomicin from all the placebo-controlled trials coupled with a systematic estimate of recurrence costs to produce a practical and easily understood comparison. By choosing to compare the drug costs vs. an estimate of the cost of a recurrence, we have not approached the question from a cost per quality adjusted life-year point of view, noting that a variety of cost-effectiveness studies have been undertaken to answer this question and most find a trivial fractional difference in quality-adjusted life-years (QALYs). More fundamentally, cost-effectiveness is not the same as cost saving. Cost-effectiveness measures, including cost per QALY and cost per incremental cost effectiveness ratio (ICER), address how much added cost ought to be paid for a subjectively perceived threshold of value. Often this is contextualized
against the historical price for a year of hemodialysis which is lifesaving. However, hospitals, patients, and governments do not have unlimited budgets and most treatments are nowhere near the same order of lifesaving as hemodialysis. Even if an intervention is perceived as valuable, if there is no money to pay for it, cost-effectiveness may be irrelevant.

CDI causes a major burden to health systems worldwide and preventing recurrences has value. Yet, health system sustainability requires thoughtful assessment of both current and future costs and benefits. At current pricing, a switch to first line fidaxomicin will cost billions of excess healthcare dollars, and these costs will not be recouped through the prevention of recurrence. Assuming vancomycin costs remain the same, and until additional trials of novel vancomycin dosing strategies are available, a reduction of the cost of fidaxomicin to below $1550USD and $800CAD respectively would certainly support a substantial change to North American prescribing practices.
Acknowledgements

TCL and EGM receive research salary support from the Fonds de Recherche du Québec – Santé.

Conflicts of Interest

EGM and TCL are principal investigators on a Canadian Institutes of Health Research Funded clinical trial looking at alternative vancomycin dosing strategies for the first episode of C. difficile.

CRediT author statement

Conceptualization - TCL, DP; Methodology - TCL; Validation - TCL, DP; Formal Analysis - TCL, DP; Investigation - TCL, DP, JS; Resources - TCL; Data Curation - TCL, DP, JS; Writing - Original Draft - DP, EGM, TCL, JS; Writing - Review and Editing - All authors; Visualization - DP, TCL; Supervision - TCL; Project administration - TCL.
<table>
<thead>
<tr>
<th>Study</th>
<th>Recurrence Cost</th>
<th>2021 dollars</th>
<th>Cost perspectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McFarland et al.¹⁹, 1999</td>
<td>$1914</td>
<td>$3186.90</td>
<td>Costs obtained from medical billing records and laboratory charges</td>
</tr>
<tr>
<td>Desai et al.¹⁶, 2016</td>
<td>$9501.74</td>
<td>$11112.38</td>
<td>Societal perspective; indirect costs (productivity loss) were excluded</td>
</tr>
<tr>
<td>Rodrigues et al.¹⁵, 2017</td>
<td>$34104</td>
<td>$39379.90</td>
<td>Not specified; Most cost values obtained from Centers for Medicare and Medicaid Services, with hospitalization cost from Healthcare Cost Utilization Project Nationwide Inpatient Sample (all-payer hospitalization database)</td>
</tr>
<tr>
<td>Zilberberg et al.¹⁸, 2017</td>
<td>$12043</td>
<td>$13566.88</td>
<td>Costs measured as Medicare payments</td>
</tr>
<tr>
<td>Zhang et al.¹⁷, 2018</td>
<td>$10580</td>
<td>$12373.41</td>
<td>Total healthcare costs were calculated as amount paid by primary and secondary insurers and by patients (i.e., copayment and deductibles) across all claims</td>
</tr>
<tr>
<td>Luo et al.¹⁴, 2020</td>
<td>$6826</td>
<td>$7418.67</td>
<td>Modified third-party payer’s perspective (included costs of medications, hospitalizations, and any procedures)</td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wagner et al.²², 2014</td>
<td>$8250.05</td>
<td>$10002.21</td>
<td>Public payer perspective</td>
</tr>
<tr>
<td>Levy et al.², 2015</td>
<td>$8157.89</td>
<td>$9420.66</td>
<td>Public payer perspective</td>
</tr>
<tr>
<td>Lapointe-Shaw et al.²¹, 2016</td>
<td>Metronidazole:$5386 Vancomycin:$5929 Mean cost:$5657.50</td>
<td>Metronidazole:$6036.77 Vancomycin:$6645.38 Mean cost:$6341.08</td>
<td>Public payer perspective</td>
</tr>
</tbody>
</table>
Figure 1 - Forest Plot of Fidaxomicin Randomized Controlled Trials Risk of Recurrent CDI

<table>
<thead>
<tr>
<th>Study</th>
<th>Risk Ratio (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louie et al. NEJM 2011</td>
<td>0.61 (0.43, 0.87)</td>
<td>45.96</td>
</tr>
<tr>
<td>Cornely et al. Lancet Inf Dis. 2012</td>
<td>0.47 (0.31, 0.71)</td>
<td>34.80</td>
</tr>
<tr>
<td>Mikamo et al. J. Infect Chemotherapy 2018</td>
<td>0.77 (0.45, 1.34)</td>
<td>19.24</td>
</tr>
<tr>
<td>Overall, REML ($I^2 = 6.2%, p = 0.345$)</td>
<td>0.58 (0.46, 0.74)</td>
<td>100.00</td>
</tr>
</tbody>
</table>

NOTE: Weights are from random-effects model
Figure 2 - Probability of Fidaxomicin Cost Equivalence - USA
Figure 3 - Probability of Fidaxomicin Cost Equivalence - Canada

The graph shows the probability of fidaxomicin cost equivalence in Canada as a function of the cost of fidaxomicin in Canadian dollars (CAD). The x-axis represents the cost of fidaxomicin (in CAD), while the y-axis represents the probability of cost equivalence in percentages. The data points are connected by a curve, indicating a higher probability of cost equivalence at lower costs of fidaxomicin.
References:


